ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics(JPT)

Vol. 26 No. 9 1998

* With abstract in English 

■ PHARMACOLOGY AND CLINICAL PHARMACOLOGY

Toxicity studies of CD-13(1)
-Single dose toxicity study of CD-13 in rats and beagle dogs-

K. Naohara, et al.

Jpn Pharmacol Ther 1998 26(9) 1333-43*


Toxicity studies of CD-13(2)
-Four week repeated dose oral toxicity study and 2-week ecovery study of CD-13 in male and female rats-

K. Naohara, et al.

Jpn Pharmacol Ther 1998 26(9) 1345-63*


Toxicity studies of CD-13(3)
-Four-week repeated dose oral toxicity study and 2-week recovery study of CD-13 in male and female beagle dogs-

K. Naohara, et al.

Jpn Pharmacol Ther 1998 26(9) 1365-91*


Reproductive and developmental toxicity studies of CD-13(1)
-Study of fertility and early embryonic development to implantation in rats-

K. Chihara, et al.

Jpn Pharmacol Ther 1998 26(9) 1393-400*


Reproductive and developmental toxicity studies of CD-13(2)
-Study for effects on embryo-fetal development in rats-

K. Chihara, et al.

Jpn Pharmacol Ther 1998 26(9) 1401-7*


Reproductive and developmental toxicity studies of CD-13(3)
-Study for effects on embryo-fetal development in rabbits-

K. Chihara, et al.

Jpn Pharmacol Ther 1998 26(9) 1409-17*


Reproductive and developmental toxicity studies of CD-13(4)
-Study for effects on prenatal and postnatal development, including maternal function-

K. Chihara, et al.

Jpn Pharmacol Ther 1998 26(9) 1419-34*


Effect of atorvastatin (YM548), a new HMG-CoA reductase inhibitor, on the regulation of cholesterol synthesis in HepG2 cells

T. Funatsu, et al.

Jpn Pharmacol Ther 1998 26(9) 1435-41


Upregulation of low density lipoprotein receptor activity and gene expression by atorvastatin (YM548), a new HMG-CoA reductase inhibitor,in HepG2 cells

T. Funatsu, et al.

Jpn Pharmacol Ther 1998 26(9) 1443-50


Time course of acute inhibition of cholesterol synthesis by YM548 in cholestylamine-primed rats

H. Tanaka, et al.

Jpn Pharmacol Ther 1998 26(9) 1451-4


Hypolipidemic effect of atorvastatin(YM548), a new HMG-CoA reductase inhibitor, in guinea pigs

T. Funatsu, et al.

Jpn Pharmacol Ther 1998 26(9) 1455-60


Effect of YM548, a New HMG-CoA reductase inhibitor, on lipid metabolism in normal guinea pig

H. Kakuta, et al.

Jpn Pharmacol Ther 1998 26(9) 1461-8


Triglyceride-lowering activity of novel HMG-CoA reductase inhibitor, YM548 in rats fed sucrose-rich diet

M. Suzuki, et al.

Jpn Pharmacol Ther 1998 26(9) 1469-74


Antiatherosclerotic effects of YM548 in Watanabe heritable hyperlipidemic rabbits

Y. Arai, et al.

Jpn Pharmacol Ther 1998 26(9) 1475-86


Effects of incadronate (YM175) on bone resorption and mineralization of cartilage in young rats

N. O'uchi, et al.

Jpn Pharmacol Ther 1998 26(9) 1487-92*


Basic study about the dosage and administration of NKH477, a novel cardiotonic drug

M. Hosono, et al.

Jpn Pharmacol Ther 1998 26(9) 1493-6


Effectiveness of NKH477 in the isolated guinea-pig heart with contractile dysfunction following post-ischemic reperfusion

T. Onda, et al.

Jpn Pharmacol Ther 1998 26(9) 1497-501


Oral mucosa irritation studies of hamsters and gastric mucosa irritation studies of rats

M. Kiguchi, et al.

Jpn Pharmacol Ther 1998 26(9) 1503-12*


Pharmaceutical development of irsogladine maleate tablets

Y. Matsuda, et al.

Jpn Pharmacol Ther 1998 26(9) 1513-7


Effects of ambroxol hydrochloride (Ponophen) on experimentally induced sinusitis in rabbits

M. Kondo, et al.

Jpn Pharmacol Ther 1998 26(9) 1519-28*


Protective effects against neuron damages, anti-fatigue and anti-stress effects of the herbal mixture, Juzen-taiho-to

T. Tsuda, et al.

Jpn Pharmacol Ther 1998 26(9) 1529-38*


Effects of terfenadine on sleeping time in electroencephalogram and electro-oculogram of rhesuses

C. Tateda, et al.

Jpn Pharmacol Ther 1998 26(9) 1539-43*

■ THERAPEUTICS

Early administration of the angiotensin-converting enzyme inhibitor imidapril attenuates ventricular remodeling after acute myocardial infarction

Y.Yoshitomi, et al.

Jpn Pharmacol Ther 1998 26(9) 1545-52*